Xenon Pharmaceuticals/$XENE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Ticker
$XENE
Sector
Trading on
Industry
Biotechnology
Headquarters
Burnaby, Canada
Employees
322
ISIN
CA98420N1050
Website
XENE Metrics
BasicAdvanced
$2.5B
-
-$3.22
1.22
-
Price and volume
Market cap
$2.5B
Beta
1.22
52-week high
$44.74
52-week low
$26.74
Average daily volume
1.2M
Financial strength
Current ratio
17.656
Quick ratio
17.43
Long term debt to equity
1.036
Total debt to equity
1.232
Profitability
EBITDA (TTM)
-290.362
Gross margin (TTM)
-2,931.25%
Net profit margin (TTM)
-3,352.61%
Operating margin (TTM)
-3,906.60%
Effective tax rate (TTM)
1.59%
Revenue per employee (TTM)
$20,000
Management effectiveness
Return on assets (TTM)
-22.03%
Return on equity (TTM)
-31.60%
Valuation
Price to revenue (TTM)
333.726
Price to book
3.48
Price to tangible book (TTM)
3.48
Price to free cash flow (TTM)
-12.528
Free cash flow yield (TTM)
-7.98%
Free cash flow per share (TTM)
-255.58%
Growth
Earnings per share change (TTM)
19.15%
3-year revenue growth (CAGR)
-31.01%
10-year revenue growth (CAGR)
-12.15%
3-year earnings per share growth (CAGR)
27.27%
10-year earnings per share growth (CAGR)
19.64%
What the Analysts think about XENE
Analyst ratings (Buy, Hold, Sell) for Xenon Pharmaceuticals stock.
Bulls say / Bears say
Analysts have set an average 12-month price target of $56.00 for Xenon Pharmaceuticals, indicating a potential upside of approximately 48% from the current trading price. (marketbeat.com)
Xenon Pharmaceuticals has a strong cash position, with cash and cash equivalents of $885.4 million as of March 31, 2024, sufficient to fund operations into 2027. (stocktitan.net)
The company's lead drug candidate, azetukalner, has demonstrated clinically meaningful activity in depression, positioning it as a potential therapeutic option for major depressive disorder. (stocktitan.net)
Xenon Pharmaceuticals reported a net loss of $47.9 million for Q1 2024, higher than the same period in 2023, primarily due to increased research and development expenses. (stocktitan.net)
The company's future success is heavily dependent on the outcomes of its clinical trials, particularly the Phase III epilepsy study and upcoming MDD trials; negative results could significantly impact stock performance. (investing.com)
The neurological disorder treatment landscape is competitive, with several established players and emerging therapies; azetukalner may face challenges in achieving market dominance upon approval. (investing.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jun 2025.
XENE Financial Performance
Revenues and expenses
XENE Earnings Performance
Company profitability
XENE News
AllArticlesVideos
Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewsWire·2 weeks ago
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·3 weeks ago
Polarean's Xenon MRI technology to feature in over 30 studies at American Thoracic Society events
Proactive Investors·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Xenon Pharmaceuticals stock?
Xenon Pharmaceuticals (XENE) has a market cap of $2.5B as of June 18, 2025.
What is the P/E ratio for Xenon Pharmaceuticals stock?
The price to earnings (P/E) ratio for Xenon Pharmaceuticals (XENE) stock is 0 as of June 18, 2025.
Does Xenon Pharmaceuticals stock pay dividends?
No, Xenon Pharmaceuticals (XENE) stock does not pay dividends to its shareholders as of June 18, 2025.
When is the next Xenon Pharmaceuticals dividend payment date?
Xenon Pharmaceuticals (XENE) stock does not pay dividends to its shareholders.
What is the beta indicator for Xenon Pharmaceuticals?
Xenon Pharmaceuticals (XENE) has a beta rating of 1.22. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.